Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 17/20 | 0.56 |
| ▸ | CTSK | P43235 | 13/20 | 0.56 |
| ▸ | CTSB | P07858 | 6/20 | 0.53 |
| ▸ | CTSL | P07711 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1329147 | 1.00 | CTSS (0.56) | CTSSCTSKCTSBCTSLMEN1 | |
| SCHEMBL29361478 | 0.92 | CTSS (0.57) | CTSSCTSKCTSBCTSLMEN1 | |
| SCHEMBL24648943 | 0.87 | CTSS (0.51) | CTSSCTSKCTSBCTSLMEN1 | |
| SCHEMBL14102904 | 0.86 | CTSS (0.62) | CTSSCTSKCTSBCTSLMEN1 | |
| SCHEMBL7759155 | 0.85 | CTSS (0.64) | CTSSCTSKCTSBCTSL | |
| SCHEMBL12127703 | 0.85 | CTSS (0.47) | CTSSCTSKCTSBCTSLMEN1 | |
| SCHEMBL14485901 | 0.85 | CTSS (0.74) | CTSSCTSKCTSBCTSL | |
| SCHEMBL2540154 | 0.84 | CTSK (0.48) | CTSSCTSKCTSBCTSLMEN1 | |
| SCHEMBL15167046 | 0.84 | CTSK (0.48) | CTSSCTSKCTSBCTSLMEN1 | |
| SCHEMBL29360411 | 0.83 | CTSS (0.54) | CTSSCTSKCTSBCTSLMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11400062-B2 | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2022-08-02 | — | — | US | disclosed |
| US-11179355-B2 | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-11179355-B2 | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200253900-A1 | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof | 3I, LP | 2020-08-13 | — | — | US | disclosed |
| US-20200253900-A1 | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof | 3I, LP | 2020-08-13 | — | — | US | disclosed |
| EP-2349241-B1 | PHARMACEUTICAL COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS | SIGNATURE THERAPEUTICS INC (US) | 2019-06-19 | — | — | EP | disclosed |
| EP-2560486-B1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF | SIGNATURE THERAPEUTICS INC (US) | 2018-11-21 | — | — | EP | disclosed |
| US-10028945-B2 | Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170119754-A1 | Compositions Comprising Enzyme-Cleavable Ketone-Modified Opioid Prodrugs and Optional Inhibitors Thereof | 3I, LP | 2017-05-04 | — | — | US | disclosed |
| US-20170119754-A1 | Compositions Comprising Enzyme-Cleavable Ketone-Modified Opioid Prodrugs and Optional Inhibitors Thereof | 3I, LP | 2017-05-04 | — | — | US | disclosed |
| WO-2011133348-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF | PHARMACOFORE, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133348-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF | PHARMACOFORE, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133149-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF | PHARMACOFORE, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133149-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF | PHARMACOFORE, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133150-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF | PHARMACOFORE, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133179-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE HYDROMORPHONE PRODRUG | PHARMACOFORE, INC (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133151-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PHENOL-MODIFIED OPIOID PRODRUGS AND INHIBITORS THEREOF | PHARMACOFORE, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| EP-2349241-A1 | PHARMACEUTICAL COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS | Pharmacofore, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2011031350-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE KETONE-MODIFIED OPIOID PRODRUGS AND OPTIONAL INHIBITORS THEREOF | PHARMACOFORE, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2010045599-A1 | PHARMACEUTICAL COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS | PHARMACOFORE, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11179355-B2 | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof | ACHE, COMT, CES2 | CTSS 166/4885CTSK 302/4885CTSB 169/4885 |
| US-20170119754-A1 | Compositions Comprising Enzyme-Cleavable Ketone-Modified Opioid Prodrugs and Optional Inhibitors Thereof | ACHE, CYP2C18, CYP2C9 | CTSS 89/4885CTSK 102/4885CTSB 157/4885 |
| US-11400062-B2 | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof | ACHE, COMT, CES2 | CTSS 166/4885CTSK 302/4885CTSB 169/4885 |
| US-10028945-B2 | Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof | ACHE, CYP2C18, CYP2C9 | CTSS 89/4885CTSK 102/4885CTSB 157/4885 |
| US-20200253900-A1 | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof | ACHE, COMT, CES2 | CTSS 166/4885CTSK 302/4885CTSB 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.